Top EU Firms Cut Investment Less than US Rivals, but Europe Still Well Behind

The European Commission's 2010 "EU Industrial R&D Investment Scoreboard" shows that R&D investment by top EU companies fell by 2.6% in 2009, even though sales and profits fell much more, by 10.1% and 21.0% respectively. The fall in R&D investment by leading players in the US, at 5.1%, was twice as sharp as in the EU, but the worldwide reduction was lower, at 1.9%. Japanese firms maintained their level of investment. Companies based elsewhere in Asia - China, India, Hong Kong, South Korea and Taiwan - continued the high R&D growth seen in previous years. Japanese car maker Toyota is the world's biggest R&D investor (€6.8bn) for the second consecutive year. Three EU companies feature in the top ten: Volkswagen, the biggest investor based in Europe with €5.8bn, Nokia and Sanofi-Aventis. The Scoreboard covers the top 1400 companies worldwide.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science said: "The fact that major EU firms have largely maintained their R&D investment shows that they recognise R&D as key to emerging stronger from the crisis. But the wide gap with the top US companies in areas like software and biotechnology and the continuing rapid rise of Asian-based companies highlight the innovation emergency Europe is facing. We urgently need heads of state and government at the December European Council to back the Innovation Union proposals that Antonio Tajani and I announced on 6 October."

This year's Scoreboard shows that despite almost unprecedentedly difficult economic conditions R&D investment remains an important strategic priority for top firms worldwide.

Trends in world regions
During 2009, leading EU companies reduced R&D investments much less than their US counterparts despite similar drops in sales (around 10%) and higher drops in profits (13.0% as against 1.4%)

European companies' R&D performance is weak in key hi-tech sectors. For example the US companies featured in the Scoreboard invested five times more than their EU counterparts in R&D on semiconductors, four times more in software R&D and eight times more in biotechnology.

Japanese companies maintained R&D investment despite strong decreases in sales (around 10%) and profits (88.2%).

Major companies headquartered in some Asian countries continued the high R&D growth of previous years, e.g. China (up 40.0%), India (27.3%), Hong Kong (14.8%), South Korea (9.1%) and Taiwan (3.1%). Swiss companies also increased R&D investment (2.5%).

Company and sector trends
Three companies headquartered in the EU are among the top ten R&D investors (Volkswagen, Nokia and Sanofi-Aventis), along with three from the US (Microsoft, Pfizer and Johnson & Johnson), and one from Japan (Toyota, in top position). The top 50 includes 16 EU companies, 19 US firms and 12 from Japan (fig. 2). 30 of the top 50 cut R&D investment in 2009.

Despite the crisis, the sectoral composition of R&D investment worldwide has remained broadly the same. For US companies, high R&D-intensity sectors, such as pharmaceutical or computer services, contribute to more than two-thirds of the total R&D. By contrast, for European and Japanese companies, medium-high R&D intensity sectors (for example automobiles or electronics) predominate, while the high R&D intensity sectors constitutes only around one-third of the total investment.

There were massive reductions in R&D investment by some automotive firms, e.g. Ford (32.4%), Renault (26.5%) and General Motors (24.1%). Others such as Nissan and Toyota showed a modest reduction or even increased R&D investment, e.g. Hyundai.

Companies boosting R&D investment in 2009 included not only those with good sales and profits such as Huawei Technologies (27.8%) and Apple (25.4%), but also some firms, such as Bayer (8.8%) and General Electric (10.1%), that increased R&D while profits and sales fell.

The alternative energy sector continued to grow rapidly. The Scoreboard now includes 15 companies (9 more than last year) fully focused on clean energy technology. These companies, 13 based in the EU and 2 elsewhere, invested more than €500 million in R&D in 2009, an increase of 28.7%. Alternative energy investments are also made by companies classified under other sectors, e.g. oil & gas.

Differences across EU - Spain's top R&D investors resist the crisis
Within the EU, R&D growth rates differ between Member States due to their varied sector composition. Some of the biggest R&D decreases in 2009 were by companies based in countries such as Germany (down 3.2%) and France (4.5%) with a large automotive industry.

Countries like Finland (down 6%) and Sweden (6.6%) where IT hardware is a major industry for home-based companies were also hit hard.

However, Spain's top R&D investors increased investment by 15.4%, despite a drop in sales of 6.4%. This was due to large increases by top Spanish companies such as Telefónica (16%) and Acciona (29%) and the inclusion of top players such as Banco Santander (18%).

The EU Industrial R&D Investment Scoreboard is published annually by the European Commission (DG Research and Joint Research Centre) and provides information on the world's top 1400 companies (400 from the EU and 1000 from outside) ranked by their investments in R&D. It measures the total value of their global R&D investment, irrespective of the location where the relevant R&D takes place. It does not therefore indicate trends in private sector R&D intensity – business R&D expenditure in a particular country or region as a proportion of GDP, whether that expenditure is by home-grown companies or through inward investment.

Download
2010 "EU Industrial R&D Investment Scoreboard" and other IRMA (Industrial Research Investment Monitoring and Analysis) reports: http://iri.jrc.ec.europa.eu/reports.htm

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...